News

The former chief health officer for Oracle sees artificial intelligence as the way to incorporate the many nonclinical factors that affect health into healthcare.

A convergence of legislative and judicial actions is creating PBM transparency, adding fiduciary responsibility, and addressing anti-competitive behavior, participants Jeffrey Hogan and Chad Worz, Pharm.D., said during a webinar sponsored by Managed Healthcare Executive and Drug Topics.

A new study found a specific brain and spinal cord circuit that appears to cause chronic pain after injury and could one day be targeted to treat pain without affecting the body's normal protective pain responses.

The pill version of Wegovy was available in January after the FDA approved it in December 2025. Eli Lillyʼs competitor, Foundayo (orforglipron) was approved by the FDA on April 1.

Nearly all U.S. adolescents who are at risk for HIV are missing out on preexposure prophylaxis, with significant disparities in access based on age, gender and geographic location.

Additionally, Orlando Health — Health Central Hospital is building a new cardiac catheterization laboratory with specialized electrophysiology equipment.

The FDA has approved two drugs for treatment of the condition, Rezdiffra (resmetirom) and Wegovy (semaglutide), the weight loss drug.

PBMs have launched clinical programs pairing GLP-1 prescriptions with pharmacist coaching, nutrition support, behavioral health partnerships, and digital tools to improve adherence and outcomes.

CMS boosts Medicare Advantage 2027 rates by 2.48%; Michael Lutz and Ceci Connolly warn MA plans still face inflation and risk-adjustment inequities.

A review of clinical trials and genetic, immune, and environmental factors revealed that Asian patients with advanced HER2-negative gastric cancer generally experience higher response rates and longer survival with immunotherapy than non-Asian patients.

A March 2026 study found that U.S. cancer patients with hypertension, hyperlipidemia or diabetes face consistently higher healthcare costs, which increased steadily from 2012 to 2018, dropped during the COVID-19 pandemic and remain elevated compared with patients without these conditions.

New research suggests that when adolescents sleep, not just how long, may play a significant role in shaping their eating habits and activity levels, particularly during the school year.

A new meta-analysis of prospective studies finds artificial intelligence performs similarly to dermatologists in melanoma detection, although more rigorous research is needed before it can be considered as a reliable decision-support tool in routine care.

The California insurer is continuing the program, called Virtual Blue, but also looking to add more virtual care into its standard offerings.

Yuvezzi treats presbyopia, or blurry vision due to aging, and is available at retail pharmacies or PHIL, an ePharmacy platform.

One year after FDA approval, Journavx (suzetrigine) offers a promising non-opioid option for acute pain, but experts have concerns about long-term safety, opioid-sparing effects and real-world use.

Lenox Hill Hospital’s controversial $2 billion redevelopment includes a new mental health clinic, a shorter tower, and expanded emergency, surgical, and maternity facilities.

Dermatology performance measures need to be streamlined and redesigned to better capture meaningful patient outcomes while reducing administrative burden and aligning with value-based care.

The two oral GLP-1s will battle for market share. Foundayo is a small-molecule drug that can be taken with food. Some data suggest that oral Wegovy is slightly better at producing weight loss.

Women who experience menopause before age 40 face a significantly higher risk of coronary heart disease, according to new research by researchers at Northwestern Medicine.

USF Health researchers have discovered how opioid receptors work in reverse, which could allow for medications to boost pain relief without causing dangerous side effects.

The Phoenix-based nonprofit health system had $16 billion in revenues in 2025 and reported $1.1 billion in community benefits in its 2025 annual report.

Doctors Without Borders has accused Gilead of restricting access to its HIV prevention drug lenacapavir by refusing humanitarian sales and limiting supply, arguing this is hindering global efforts to expand HIV prevention in high-need regions.

A new report found that despite widespread AI adoption in U.S. health systems, many patients still struggle to access care due to gaps in communication, trust and care navigation.

Alkermes has initiated a phase 3 clinical program evaluating alixorexton for narcolepsy type 1 and type 2, with additional development underway for idiopathic hypersomnia.

A long-term extension trial of 389 patients found Attruby significantly cut death risk in transthyretin amyloid cardiomyopathy, with no new safety concerns identified.

Eli Lilly announced this morning that the FDA has approved its oral GLP-1, orforglipron, which the company is marketing under the brand name Foundayo. The competition between Foundayo and oral Wegovy is expected to be fierce.

A new preclinical study found that inhibiting the enzyme LSD1 can activate the skin’s immune system and suppress tumor growth, pointing to a potential new topical treatment for skin cancer.